poisar

Stocks · News reference

Upstream Bio Q2 EPS $(0.73) Beats $(0.76) Estimate, Sales $773.000K Beat $430.714K Estimate

Benzinga Newsdesk

Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.76) by 3.95 percent. This is a 1.35 percent increase over losses of $(0.74) per share from the

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

UPB
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Not Specified

    Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

    Upstream Bio announced positive Phase 2 VALIANT trial results for verekitug, a TSLP receptor antagonist, showing a 56% reduction in annualized asthma exacerbation rate at 100 mg every 12 weeks versus placebo. The company plans to initiate Phase 3 trials in Q1 2027 evaluating a 400 mg quarterly dosing regimen in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

    UPB